Skip to main content
Erschienen in:

18.09.2024 | Original Article

Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prevention of Gastric and/or Duodenal Ulcers: A Systematic Review with Meta-Analysis

verfasst von: Daniel Martin Simadibrata, Elvira Lesmana, Muhammad Iqbal Adi Pratama, Adrianus Jonathan Sugiharta, Ayers Gilberth Ivano Kalaij, Arzita Diandra Diva Fadhilla, Pojsakorn Danpanichkul, Ari Fahrial Syam, Marcellus Simadibrata

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Although Vonoprazan, a potassium-competitive acid blocker, is superior to proton pump inhibitors (PPIs) in treating Helicobacter pylori and erosive esophagitis, its efficacy for treating gastric and/or duodenal ulcers remains controversial. This meta-analysis summarizes the efficacy and safety of Vonoprazan vs. PPI for treating and preventing gastric and/or duodenal ulcers.

Methods

Only randomized controlled trials randomizing gastric and/or duodenal ulcer patients, regardless of etiology, into Vonoprazan or any PPI and indexed in Embase, Medline, and CENTRAL until March 2, 2024 were searched. Primary outcomes were ulcer healing rates at Weeks 2, 4, 6, and 8 and recurrence rates at Week 24. Other outcomes included shrinkage rates, any adverse events (AEs), serious AEs (SAEs), and risks of delayed bleeding and perforation. The overall risk ratio (RR) and mean difference were pooled using the random-effects model. The risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB2) Tool.

Results

Fifteen studies comprising 43 reports were included in the analysis. Healing rates of gastric and/or duodenal ulcers were similar in both Vonoprazan and PPI groups at all weeks (Week 2 RR 1.02 [95% CI 0.89–1.16]; Week 4 0.99 [95% CI 0.95–1.04]; Week 6 1.00 [95% CI 0.96–1.03]; Week 8 0.99 [95% CI 0.95–1.03]). The recurrence prevention of peptic ulcers was not different in Vonoprazan 10 mg (RR 0.48; 95% CI 0.18–1.27) or 20 mg (0.60; 95% CI 0.28–1.30) to PPI. Shrinkage rates, any AEs, SAEs, and risks of delayed bleeding and perforation were similar in both groups.

Conclusion

Vonoprazan is not significantly better than PPI in treating and preventing gastric and/or duodenal ulcers.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Xie X, Ren K, Zhou Z, Dang C, Zhang H. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. BMC Gastroenterol. 2022;22:58.CrossRefPubMedPubMedCentral Xie X, Ren K, Zhou Z, Dang C, Zhang H. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. BMC Gastroenterol. 2022;22:58.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. The American Journal of Medicine. 2019;132:447–456.CrossRefPubMed Kavitt RT, Lipowska AM, Anyane-Yeboa A, Gralnek IM. Diagnosis and treatment of peptic ulcer disease. The American Journal of Medicine. 2019;132:447–456.CrossRefPubMed
4.
Zurück zum Zitat Tarasconi A, Coccolini F, Biffl WL, Tomasoni M, Ansaloni L, Picetti E et al. Perforated and bleeding peptic ulcer: WSES guidelines. World J Emerg Surg. 2020;15:3.CrossRefPubMedPubMedCentral Tarasconi A, Coccolini F, Biffl WL, Tomasoni M, Ansaloni L, Picetti E et al. Perforated and bleeding peptic ulcer: WSES guidelines. World J Emerg Surg. 2020;15:3.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Muraki Y, Enomoto S, Iguchi M, Fujishiro M, Yahagi N, Ichinose M. Management of bleeding and artificial gastric ulcers associated with endoscopic submucosal dissection. World J Gastrointest Endosc. 2012;4:1–8.CrossRefPubMedPubMedCentral Muraki Y, Enomoto S, Iguchi M, Fujishiro M, Yahagi N, Ichinose M. Management of bleeding and artificial gastric ulcers associated with endoscopic submucosal dissection. World J Gastrointest Endosc. 2012;4:1–8.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Veettil SK, Sadoyu S, Bald EM, Chandran VP, Khuu SAT, Pitak P et al. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol. 2022;88:1551–1566.CrossRefPubMed Veettil SK, Sadoyu S, Bald EM, Chandran VP, Khuu SAT, Pitak P et al. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol. 2022;88:1551–1566.CrossRefPubMed
7.
Zurück zum Zitat Marabotto E, Ziola S, Savarino V, Giannini EG, Furnari M, Bodini G et al. Vonoprazan fumarate for the treatment of gastric ulcers: A short review on emerging data. Clin Exp Gastroenterol. 2020;13:99–104.CrossRefPubMedPubMedCentral Marabotto E, Ziola S, Savarino V, Giannini EG, Furnari M, Bodini G et al. Vonoprazan fumarate for the treatment of gastric ulcers: A short review on emerging data. Clin Exp Gastroenterol. 2020;13:99–104.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Kondo M, Kawamoto M, Hasuoka A, Kajino M, Inatomi N, Tarui N. High-throughput screening of potassium-competitive acid blockers. J Biomol Screen. 2012;17:177–182.CrossRefPubMed Kondo M, Kawamoto M, Hasuoka A, Kajino M, Inatomi N, Tarui N. High-throughput screening of potassium-competitive acid blockers. J Biomol Screen. 2012;17:177–182.CrossRefPubMed
9.
Zurück zum Zitat Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:2217–2228.CrossRefPubMedPubMedCentral Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:2217–2228.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Chandan S, Deliwala S, Mohan BP, Ramai D, Dhindsa B, Bapaye J et al. Vonoprazan versus lansoprazole in erosive esophagitis—A systematic review and meta-analysis of randomized controlled trials. Indian J Gastroenterol. 2023;42:475–484.CrossRefPubMed Chandan S, Deliwala S, Mohan BP, Ramai D, Dhindsa B, Bapaye J et al. Vonoprazan versus lansoprazole in erosive esophagitis—A systematic review and meta-analysis of randomized controlled trials. Indian J Gastroenterol. 2023;42:475–484.CrossRefPubMed
11.
Zurück zum Zitat Jaruvongvanich V, Poonsombudlert K, Ungprasert P. Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:1416–1421.CrossRefPubMed Jaruvongvanich V, Poonsombudlert K, Ungprasert P. Vonoprazan versus proton-pump inhibitors for gastric endoscopic submucosal dissection-induced ulcers: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:1416–1421.CrossRefPubMed
12.
Zurück zum Zitat Martin ZY, Meng CX, Takagi T, Tian YS. Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: A meta-analysis of randomized controlled trials and observational studies. Medicine (Baltimore). 2020;99:e19357.CrossRefPubMedPubMedCentral Martin ZY, Meng CX, Takagi T, Tian YS. Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: A meta-analysis of randomized controlled trials and observational studies. Medicine (Baltimore). 2020;99:e19357.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews. 2021;10:89.CrossRefPubMedPubMedCentral Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews. 2021;10:89.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Gordon HG, Andrew DO, Gunn EV, Regina K, Yngve F-Y, Pablo A-C et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924.CrossRef Gordon HG, Andrew DO, Gunn EV, Regina K, Yngve F-Y, Pablo A-C et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924.CrossRef
16.
Zurück zum Zitat Dettori JR, Norvell DC, Chapman JR. Fixed-effect vs random-effects models for meta-analysis: 3 points to consider. Global Spine J. 2022;12:1624–1626.CrossRefPubMedPubMedCentral Dettori JR, Norvell DC, Chapman JR. Fixed-effect vs random-effects models for meta-analysis: 3 points to consider. Global Spine J. 2022;12:1624–1626.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M. Chapter 10: Analysing data and undertaking meta-analyses| Cochrane Training. Cochrane handbook for systematic reviews of interventions version. 2021 Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M. Chapter 10: Analysing data and undertaking meta-analyses| Cochrane Training. Cochrane handbook for systematic reviews of interventions version. 2021
18.
Zurück zum Zitat Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452–1458.CrossRefPubMed Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4:1452–1458.CrossRefPubMed
19.
Zurück zum Zitat Koizumi A, Yamashita H, Okada A. Comparison of lansoprazole with vonoprazan for treating post-endoscopic submucosal dissection ulcers. United European Gastroenterology Journal. 2016;4:A387–A388. Koizumi A, Yamashita H, Okada A. Comparison of lansoprazole with vonoprazan for treating post-endoscopic submucosal dissection ulcers. United European Gastroenterology Journal. 2016;4:A387–A388.
20.
Zurück zum Zitat Takahashi K, Sato Y, Kohisa J, Watanabe J, Sato H, Mizuno K et al. Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers. World Journal of Gastrointestinal Endoscopy. 2016;8:716–722.CrossRefPubMedPubMedCentral Takahashi K, Sato Y, Kohisa J, Watanabe J, Sato H, Mizuno K et al. Vonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers. World Journal of Gastrointestinal Endoscopy. 2016;8:716–722.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Tsuchiya I, Kato Y, Tanida E, Masui Y, Kato S, Nakajima A et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial. Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society. 2017;29:576–583.CrossRefPubMed Tsuchiya I, Kato Y, Tanida E, Masui Y, Kato S, Nakajima A et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: Prospective randomized controlled trial. Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society. 2017;29:576–583.CrossRefPubMed
22.
Zurück zum Zitat Hamada K, Uedo N, Tonai Y, Arao M, Suzuki S, Iwatsubo T et al. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. Journal of Gastroenterology. 2019;54:122–130.CrossRefPubMed Hamada K, Uedo N, Tonai Y, Arao M, Suzuki S, Iwatsubo T et al. Efficacy of vonoprazan in prevention of bleeding from endoscopic submucosal dissection-induced gastric ulcers: a prospective randomized phase II study. Journal of Gastroenterology. 2019;54:122–130.CrossRefPubMed
23.
Zurück zum Zitat Hirai A, Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S et al. Comparison of the effects of vonoprazan and lansoprazole for treating endoscopic submucosal dissection-induced artificial ulcers. Digestive Diseases and Sciences. 2018;63:974–981.CrossRefPubMed Hirai A, Takeuchi T, Takahashi Y, Kawaguchi S, Ota K, Harada S et al. Comparison of the effects of vonoprazan and lansoprazole for treating endoscopic submucosal dissection-induced artificial ulcers. Digestive Diseases and Sciences. 2018;63:974–981.CrossRefPubMed
24.
Zurück zum Zitat Ishii Y, Yamada H, Sato T, Sue S, Kaneko H, Irie K et al. Effects of vonoprazan compared with esomeprazole on the healing of artificial postendoscopic submucosal dissection ulcers: a prospective, multicenter, two-arm, randomized controlled trial. Gastroenterology Research and Practice. 2018;2018:1615092.CrossRefPubMedPubMedCentral Ishii Y, Yamada H, Sato T, Sue S, Kaneko H, Irie K et al. Effects of vonoprazan compared with esomeprazole on the healing of artificial postendoscopic submucosal dissection ulcers: a prospective, multicenter, two-arm, randomized controlled trial. Gastroenterology Research and Practice. 2018;2018:1615092.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Ichida T, Ueyama S, Eto T, Kusano F, Sakai Y. Randomized controlled trial comparing the effects of vonoprazan plus rebamipide and esomeprazole plus rebamipide on gastric ulcer healing induced by endoscopic submucosal dissection. Internal Medicine (Tokyo, Japan). 2019;58:159–166.CrossRefPubMed Ichida T, Ueyama S, Eto T, Kusano F, Sakai Y. Randomized controlled trial comparing the effects of vonoprazan plus rebamipide and esomeprazole plus rebamipide on gastric ulcer healing induced by endoscopic submucosal dissection. Internal Medicine (Tokyo, Japan). 2019;58:159–166.CrossRefPubMed
26.
Zurück zum Zitat Komori H, Ueyama H, Nagahara A, Akazawa Y, Takeda T, Matsumoto K et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. Journal of International Medical Research. 2019;47:1441–1452.CrossRefPubMedPubMedCentral Komori H, Ueyama H, Nagahara A, Akazawa Y, Takeda T, Matsumoto K et al. A prospective randomized trial of a potassium competitive acid blocker vs proton pump inhibitors on the effect of ulcer healing after endoscopic submucosal dissection of gastric neoplasia. Journal of International Medical Research. 2019;47:1441–1452.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Ban H, Inatomi O, Murata M, Otsuka T, Oi M, Matsumoto H et al. Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study. Journal of Clinical Biochemistry and Nutrition. 2021;68:259–263.CrossRefPubMed Ban H, Inatomi O, Murata M, Otsuka T, Oi M, Matsumoto H et al. Vonoprazan vs lansoprazole for the treatment of artificial gastric ulcer after endoscopic submucosal dissection: a prospective randomized comparative study. Journal of Clinical Biochemistry and Nutrition. 2021;68:259–263.CrossRefPubMed
28.
Zurück zum Zitat Kawai D, Takenaka R, Ishiguro M, Okanoue S, Gotoda T, Kono Y et al. Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial. BMC Gastroenterology. 2021;21:236.CrossRefPubMedPubMedCentral Kawai D, Takenaka R, Ishiguro M, Okanoue S, Gotoda T, Kono Y et al. Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial. BMC Gastroenterology. 2021;21:236.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers—results from two phase 3, non-inferiority randomised controlled trials. Alimentary Pharmacology and Therapeutics 2017;45:240–252.CrossRefPubMed Miwa H, Uedo N, Watari J, Mori Y, Sakurai Y, Takanami Y et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers—results from two phase 3, non-inferiority randomised controlled trials. Alimentary Pharmacology and Therapeutics 2017;45:240–252.CrossRefPubMed
31.
Zurück zum Zitat Hou X, Meng F, Wang J, Sha W, Chiu C-T, Chung WC et al. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. Journal of Gastroenterology and Hepatology. 2022;37:1275–1283.CrossRefPubMed Hou X, Meng F, Wang J, Sha W, Chiu C-T, Chung WC et al. Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. Journal of Gastroenterology and Hepatology. 2022;37:1275–1283.CrossRefPubMed
32.
Zurück zum Zitat Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67:1042–1051.CrossRefPubMed Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67:1042–1051.CrossRefPubMed
33.
Zurück zum Zitat Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2017;67:1033–1041.CrossRefPubMed Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut. 2017;67:1033–1041.CrossRefPubMed
34.
Zurück zum Zitat Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: A systematic review with meta-analysis. Medicine (Baltimore). 2019;98:e15860.CrossRefPubMedPubMedCentral Kang H, Kim BJ, Choi G, Kim JG. Vonoprazan versus proton pump inhibitors for the management of gastric endoscopic submucosal dissection-induced artificial ulcer: A systematic review with meta-analysis. Medicine (Baltimore). 2019;98:e15860.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Liu C, Feng BC, Zhang Y, Li LX, Zuo XL, Li YQ. The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta-analysis. J Dig Dis. 2019;20:503–511.CrossRefPubMed Liu C, Feng BC, Zhang Y, Li LX, Zuo XL, Li YQ. The efficacy of vonoprazan for management of post-endoscopic submucosal dissection ulcers compared with proton pump inhibitors: A meta-analysis. J Dig Dis. 2019;20:503–511.CrossRefPubMed
36.
Zurück zum Zitat Miao T, Zhang Y, Bai L, Yang X, Wen X. Vonoprazan vs. lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2023;115:168–174.PubMed Miao T, Zhang Y, Bai L, Yang X, Wen X. Vonoprazan vs. lansoprazole for the treatment of endoscopic submucosal dissection induced gastric ulcer: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2023;115:168–174.PubMed
37.
Zurück zum Zitat 陈旋, 徐梦婷, 文剑波. 新型抑酸剂沃诺拉赞与传统 PPIs 预防胃 ESD 术后迟发性出血和促进人造溃疡愈合比较的 Meta 分析: 2474 例. 世界华人消化杂志. 2020;28(24):1249–1260. 陈旋, 徐梦婷, 文剑波. 新型抑酸剂沃诺拉赞与传统 PPIs 预防胃 ESD 术后迟发性出血和促进人造溃疡愈合比较的 Meta 分析: 2474 例. 世界华人消化杂志. 2020;28(24):1249–1260.
38.
Zurück zum Zitat Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. New England Journal of Medicine. 2020;382:674–678.CrossRefPubMed Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. New England Journal of Medicine. 2020;382:674–678.CrossRefPubMed
39.
Zurück zum Zitat Abe H, Hatta W, Ogata Y, Koike T, Saito M, Jin X et al. Prevention of delayed bleeding with vonoprazan in upper gastrointestinal endoscopic treatment. J Gastroenterol. 2021;56:640–650.CrossRefPubMed Abe H, Hatta W, Ogata Y, Koike T, Saito M, Jin X et al. Prevention of delayed bleeding with vonoprazan in upper gastrointestinal endoscopic treatment. J Gastroenterol. 2021;56:640–650.CrossRefPubMed
40.
Zurück zum Zitat Cheng HC, Sheu BS. Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits. World J Gastrointest Endosc. 2011;3:49–56.CrossRefPubMedPubMedCentral Cheng HC, Sheu BS. Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits. World J Gastrointest Endosc. 2011;3:49–56.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24:334–344.CrossRefPubMedPubMedCentral Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24:334–344.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Dong Y, Xu H, Zhang Z, Zhou Z, Zhang Q. Comparative efficiency and safety of potassium competitive acid blockers versus lansoprazole in peptic ulcer: a systematic review and meta-analysis. Frontiers in Pharmacology. 2024;14:1304552.CrossRefPubMedPubMedCentral Dong Y, Xu H, Zhang Z, Zhou Z, Zhang Q. Comparative efficiency and safety of potassium competitive acid blockers versus lansoprazole in peptic ulcer: a systematic review and meta-analysis. Frontiers in Pharmacology. 2024;14:1304552.CrossRefPubMedPubMedCentral
Metadaten
Titel
Vonoprazan vs. Proton Pump Inhibitors for Treatment and Prevention of Gastric and/or Duodenal Ulcers: A Systematic Review with Meta-Analysis
verfasst von
Daniel Martin Simadibrata
Elvira Lesmana
Muhammad Iqbal Adi Pratama
Adrianus Jonathan Sugiharta
Ayers Gilberth Ivano Kalaij
Arzita Diandra Diva Fadhilla
Pojsakorn Danpanichkul
Ari Fahrial Syam
Marcellus Simadibrata
Publikationsdatum
18.09.2024
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 10/2024
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08593-5

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

NRG1-Fusionen als neues, klinisch relevantes Target

Ergebnisse einer Phase-II-Studie deuten darauf hin, dass ein gegen HER3 und HER2 gerichteter Antikörper bei verschiedenen NRG1-Fusions-positiven Tumoren wirksam sein könnte. In den USA ist die Substanz bereits beschleunigt zugelassen worden.

Die aktuelle S3-Leitlinie zu CLL strotzt vor Neuerungen

Vor kurzem wurde eine neue, grundlegend überarbeite Version der S3-Leitlinie Chronische Lymphatische Leukämie (CLL) veröffentlicht.  Zu den wichtigsten Änderungen gehört, dass die Chemoimmuntherapie auf dem Rückzug ist.

Obinutuzumab verbessert Therapie der Lupus-Nephritis

In einer internationalen Studie führte die zusätzliche Gabe von Obinutuzumab zur Standardtherapie bei fast der Hälfte der Patientinnen und Patienten mit Lupus-Nephritis zu einem vollständigen Ansprechen der Nieren und war damit wirksamer als die Standardtherapie allein.

Appendizitis und Darminfarkt durch Blinddarm-Lipom

Eigentlich sind Lipome recht harmlos. Im Zäkum können sie jedoch erhebliche Komplikationen mit Darminfarkt und Appendizitis verursachen.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.